Oppenheimer Downgrades Editas Medicine to Perform From Outperform, Adjusts Price Target to $12 From $28 - Marketscreener.com

2 years ago 39

Delayed Nasdaq  -  04:00 2022-11-17 p.m. EST 11.01 USD   -10.12%

11/18/2022 | 08:54am EST MT Newswires 2022 All quality about EDITAS MEDICINE, INC. 08:54a Oppenheimer Downgrades Editas Medicine to Perform From Outperform, Adjusts Price Target.. MT 08:12a Credit Suisse Downgrades Editas Medicine to Neutral From Outperform After LCA10 Program.. MT 08:02a Chardan Lowers Price Target connected Editas Medicine to $35 From $43, Maintains Buy Rating MT 07:42a RBC Slashes Price Target connected Editas Medicine to $14 From $32 Amid Deprioritization of LC.. MT 11/17 Editas Medicine : EDIT-101 BRILLIANCE Clinical Trial Update November 2022 PU 11/17 Transcript : Editas Medicine, Inc. - Special Call CI 11/17 Editas Medicine, Inc. : Other Events, Financial Statements and Exhibits (form 8-K) AQ 11/17 Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from.. GL 11/17 Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from.. AQ 11/17 Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-10.. CI Analyst Recommendations on EDITAS MEDICINE, INC. 08:54a Oppenheimer Downgrades Editas Medicine to Perform From Outperform, Adjusts Price Target.. MT 08:12a Credit Suisse Downgrades Editas Medicine to Neutral From Outperform After LCA10 Program.. MT 08:02a Chardan Lowers Price Target connected Editas Medicine to $35 From $43, Maintains Buy Rating MT		Financials (USD) Sales 2022 17,1 M - - Net income 2022 -222 M - - Net currency 2022 361 M - - P/E ratio 2022 -3,43x Yield 2022 - Capitalization 741 M 741 M - EV / Sales 2022 22,2x EV / Sales 2023 24,5x Nbr of Employees 264 Free-Float 99,5% Chart EDITAS MEDICINE, INC. Duration : Period : Technical investigation trends EDITAS MEDICINE, INC. Short Term Mid-Term Long Term Trends Neutral Neutral Bearish Income Statement Evolution Consensus Sell Buy Mean consensus HOLD Number of Analysts 18 Last Close Price 11,01 $ Average people price 18,47 $ Spread / Average Target 67,7% EPS Revisions Managers and Directors Gilmore ONeill President, Chief Executive Officer & Director Michelle Robertson Chief Financial Officer & Treasurer James C. Mullen Executive Chairman Mark S. Shearman Chief Scientific Officer & Executive VP Mei Baisong Chief Medical Officer & Senior Vice President Sector and Competitors 1st jan. Capi. (M$) EDITAS MEDICINE, INC. -58.53% 741 MODERNA, INC. -27.59% 70 651 IQVIA HOLDINGS INC. -25.07% 39 269 LONZA GROUP AG -34.85% 38 546 ALNYLAM PHARMACEUTICALS, INC. 23.32% 25 728 SEAGEN INC. -14.92% 24 421

1. Homepage
2. Health
3. Oppenheimer Downgrades Editas Medicine to Perform From Outperform, Adjusts Price Target to $12 From $28 - Marketscreener.com